Effects of Ripasudil on Patients with Fuchs' Endothelial Dystrophy Undergoing Cataract Surgery
Official title: The Effects of Ripasudil in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery
Run by Singapore Eye Research Institute · NCT06048380 · Data updated 2026-11-12
This study is testing if a new eye drop called ripasudil can help people with Fuchs' Endothelial Dystrophy have better results after cataract surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 100 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Singapore Eye Research Institute Academic / other |
| Locations | 1 site (Singapore, Singapore) |
| Status | Recruiting |
| Started | March 1, 2025 |
| Main results expected | July 2025 |
| Study ends | July 2025 |
| Registry record updated | January 29, 2025 |
| Trial ID | NCT06048380 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients over 50 years old diagnosed with Fuchs' Endothelial Dystrophy who are scheduled for cataract surgery.
✕Probably not a fit
Patients with only one functioning eye or those with other significant eye diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the impact of ripasudil, an ophthalmic solution, on patients with Fuchs' Endothelial Dystrophy (FED) who are undergoing femtosecond laser-assisted cataract surgery. Participants will be randomly assigned to receive either ripasudil or a placebo, allowing researchers to evaluate the clinical outcomes and identify which patients benefit most from the treatment. The study also aims to monitor any adverse effects associated with ripasudil administration. By analyzing pre-operative parameters, the trial seeks to enhance understanding of patient characteristics that predict treatment success.
Why it matters
Potential benefit: If successful, this treatment could improve corneal endothelial function and reduce cell loss after cataract surgery in patients with FED.
How similar studies have gone: While the use of ROCK inhibitors like ripasudil is promising, this specific application in FED patients undergoing cataract surgery is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with FED who will be listed for cataract surgery as part of standard clinical practice (A cataract will be defined as clouding of the lens that interferes with normal vision). 2. Only patients older than 50 years will be included, as cataracts develops with increasing age. No gender criteria are applied. 3. Ability to provide informed consent, and are willing and able to sign a written Informed Consent Form prior to any study-specific procedures. 4. Patients must be willing and able to return for scheduled follow-up examinations for up to 12 months after the surgery. Exclusion Criteria: 1. Patients who are unable to give consent. 2. An only-functioning eye in a patient who has lost visual potential in the contralateral eye. 3. Diagnosis of clinically relevant eye diseases that may interfere with the aim of the study. 4. History of ripasudil use, as well as other systemic disease such as cardiovascular or renal disease. 5. Patients who have previous allergic reactions to the contents present in Glanatec Ophthalmic solution 0.4%
Where it's running
-
Singapore National Eye Centre
Singapore, Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Marcus Ang — Singapore Eye Research Institute
- Study coordinator: Marcus Ang
- Email: Marcus.Ang@Singhealth.com.sg
- Phone: +65 62277255
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rotational Stability of the Acunex Vario Toric
This study tests whether the Acunex Vario toric extended-depth-of-focus intraocular lens stays stable in rotation and effectively reduces astigmatism for people undergoing cataract surgery.
-
Anterior segment anatomy assessment with swept-source OCT in eye surgery patients
This study tests whether swept-source OCT can detail front-eye anatomy in patients undergoing anterior segment eye surgery.
-
MiLOOP-assisted cataract surgery for dense cataracts
In people with dense cataracts, this study tests whether using the miLOOP device during cataract surgery can protect corneal cells and reduce ultrasound energy, compared with standard surgery.
-
Visual adaptation and quality of life after different IOL implantation options
This study follows adults who have cataracts and receive bilateral multifocal or mixed IOLs to see how their vision and daily life improve over 6 months.
-
EO2002 therapy for corneal edema due to endothelial dysfunction
This trial tests whether a single intracameral injection of EO2002 cells can improve vision and reduce corneal thickness in adults with corneal edema from endothelial dysfunction.
-
Corneal Biomechanics and Surgical Astigmatism after Cataract Surgery in Pseudoexfoliation
This study tests how the cornea's biomechanical properties before cataract surgery relate to the amount of blinking surgically induced astigmatism, comparing people with pseudoexfoliation to those without.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.